ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer
Cetuximab is one of the most valuable targeted therapy monoclonal antibodies in the treatment of metastatic colorectal cancer (CRC). However, the mechanisms affecting cetuximab resistance in CRC treatment remain unclear. Metabolism, especially fatty acid metabolism, has been reported to play an impo...
Main Authors: | Hong Hi-Ju, Shao Yanfei, Zhang Sen, Yang Guang, Jia Hongtao, Yang Xiao, Huang Ling, Li Shuchun, Aikemu Batuer, Zhang Luyang, Ma Junjun, Zang Lu, Sun Jing, Zheng Minhua |
---|---|
Format: | Article |
Language: | English |
Published: |
China Science Publishing & Media Ltd.
2022-09-01
|
Series: | Acta Biochimica et Biophysica Sinica |
Subjects: | |
Online Access: | https://www.sciengine.com/doi/10.3724/abbs.2022121 |
Similar Items
-
Identification of methylation pattern in the partial promoter of acetyl CoA carboxylase beta (ACACB) gene in White Leghorn line
by: C H SHIVAPRASAD, et al.
Published: (2023-07-01) -
Cetuximab-Induced Aseptic Meningitis in a Patient with Colorectal Cancer: A Case Report and Review of Literature
by: Jakob Jäger, et al.
Published: (2022-11-01) -
Efficacy of Liver Chemoembolization after Prior Cetuximab Monotherapy in Patients with Metastatic Colorectal Cancer
by: Marcin Szemitko, et al.
Published: (2023-01-01) -
Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection
by: Yi-Chia Su, et al.
Published: (2022-04-01) -
Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report
by: Ahmad KH Ibrahimi, et al.
Published: (2023-06-01)